GSK
GSK plc$53.04
LiveJun 12, 2026
Market cap
$106.31B
52w range
35.45 – 61.70
P / E
—
EPS
—
Volume
3.81M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on GSK plc’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $52.45 (-1.11%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +4.02% | +4.08% | -0.66% | +8.67% | +8.16% | +31.00% | +53.87% | +31.00% | +32.43% | +7982.29% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$53.50
Bid
$52.00
500 sh
Ask
$53.60
1,400 sh
Spread
$1.600
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Basic Materials+2.94%
- Utilities+2.58%
- Industrials+2.57%
- Consumer Cyclical+1.53%
- Consumer Defensive+0.71%
- Financial Services+0.33%
- Real Estate-0.10%
- Technology-0.75%
- Communication Services-0.77%
- Healthcare-1.62%
- Energy-2.78%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.46%
- Copper+6.43%
- Silver+6.40%
- Engineering & Construction+4.75%
- Broadcasting+4.37%
- Furnishings, Fixtures & Appliances+4.28%
- Department Stores-3.97%
- Integrated Freight & Logistics+3.63%
- Construction Materials-3.39%
- Independent Power Producers+3.33%
- Gold+3.25%
- Apparel - Footwear & Accessories+3.16%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorderzacks.com·Jun 12, 2026
- Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com·Jun 11, 2026
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·Jun 11, 2026
- Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·Jun 11, 2026
- GSK plc (GSK) M&A Call Transcriptseekingalpha.com·Jun 10, 2026
- GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analystsproactiveinvestors.co.uk·Jun 10, 2026
- After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion dealwsj.com·Jun 09, 2026
- GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyoutzacks.com·Jun 09, 2026
Recent analyst activity
DB- Jun 09, 2026GradeOutperform → OutperformRBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'RBC Capital
Peers
No peer list available for GSK.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|